Sensei Biotherapeutics (NASDAQ:FTH) CFO Buys 5,000 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 5,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was purchased at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the acquisition, the chief financial officer owned 46,688 shares in the company, valued at $1,097,168. The trade was a 11.99% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Sensei Biotherapeutics Trading Down 5.4%

Shares of NASDAQ:FTH traded down $1.34 during trading on Wednesday, reaching $23.66. The stock had a trading volume of 114,325 shares, compared to its average volume of 89,623. Sensei Biotherapeutics, Inc. has a 52 week low of $6.32 and a 52 week high of $36.76. The stock has a market capitalization of $31.70 million, a P/E ratio of -0.17 and a beta of -0.26.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on FTH shares. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a research report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price objective for the company. BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. HC Wainwright began coverage on Sensei Biotherapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $60.00 price target on the stock. Finally, Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Buy” and an average price target of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.